SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

DermTech, Inc. – ‘S-8’ on 9/16/22

On:  Friday, 9/16/22, at 4:14pm ET   ·   Effective:  9/16/22   ·   Accession #:  1651944-22-45   ·   File #s:  333-263484, 333-267469

Previous ‘S-8’:  ‘S-8’ on 3/11/22   ·   Next:  ‘S-8’ on 3/3/23   ·   Latest:  ‘S-8’ on 3/7/24   ·   13 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 9/16/22  DermTech, Inc.                    S-8         9/16/22    5:265K

Registration Statement – Securities for an Employee Benefit Plan   —   Form S-8   —   SA’33

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-8         Registration Statement - Securities for an          HTML     84K 
                Employee Benefit Plan                                            
 2: EX-5.1      Opinion of Counsel re: Legality                     HTML     11K 
 3: EX-23.1     Consent of Expert or Counsel                        HTML      5K 
 5: EX-FILING FEES  Filing Fees                                     HTML     19K 
 4: EX-99.1     Miscellaneous Exhibit                               HTML    112K 


‘S-8’   —   Registration Statement – Securities for an Employee Benefit Plan

Document Table of Contents

Page (sequential)   (alphabetic) Top
 
11st Page  –  Filing Submission
"Powers of Attorney (included on signature page to this Registration Statement)

This is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C:   C: 
  Document  

As filed with the Securities and Exchange Commission on September 16, 2022
    REGISTRATION NO. 333 -
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
    
FORM S-8
REGISTRATION STATEMENT
under the
SECURITIES ACT OF 1933
    
DERMTECH, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware84-2870849
(State or Other Jurisdiction
(I.R.S. Employer
of Incorporation or Organization)
Identification No.)

11099 N. Torrey Pines Road, Suite 100
La Jolla, CA 92037
(Address, Including Zip Code, of Principal Executive Offices)

DermTech, Inc. Amended and Restated 2022 Inducement Equity Incentive Plan
(Full Title of the Plan)
Kevin Sun
Chief Financial Officer
DermTech, Inc.
11099 N. Torrey Pines Road, Suite 100
La Jolla, CA 92037
(858) 450-4222
(Name, Address and Telephone Number, Including
Area Code, of Agent For Service)
    
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filerxAccelerated filero
Non-accelerated fileroSmaller reporting companyx
Emerging growth companyo
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.




EXPLANATORY NOTE
    On September 1, 2022, DermTech, Inc. (the “Registrant”) amended and restated the DermTech, Inc. 2022 Inducement Equity Incentive Plan to increase the number of shares reserved for issuance pursuant to awards granted thereunder by 1,000,000 shares (the “Additional Inducement Shares”) of common stock, par value $0.0001 per share, as set forth in the DermTech, Inc. Amended and Restated 2022 Inducement Equity Incentive Plan (the “Inducement Plan”) filed with this registration statement on Form S-8 (this “Registration Statement”) as Exhibit 99.1. This Registration Statement registers the Additional Inducement Shares reserved for issuance under the Inducement Plan to employees of the Registrant as an inducement material to entry into employment with the Registrant, in accordance with Nasdaq Listing Rule 5635(c)(4). This Registration Statement registers additional securities of the same class as other securities for which a registration statement filed on Form S-8 of the Registrant relating to an employee benefit plan is effective (File No. 333-263484). The information contained in the Registrant’s registration statement on Form S‑8 (File No. 333-263484) is hereby incorporated by reference pursuant to General Instruction E of Form S-8.




PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The following documents filed by the Registrant with the Securities and Exchange Commission (the “Commission”) are incorporated herein by reference:
our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 10, 2022;
our Quarterly Reports on Form 10-Q for the quarter ended March 31, 2022 filed with the SEC on May 3, 2022 and the quarter ended June 30, 2022 filed with the SEC on August 8, 2022.
our Current Reports on Form 8-K filed with the SEC on April 28, 2022, May 3, 2022, May 31, 2022, July 18, 2022 and August 8, 2022 (except for the information furnished under Items 2.02 or 7.01 and the exhibits thereto); and
the description of our common stock contained in Exhibit 4.12 of our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 5, 2021, and any amendment or report filed with the SEC for the purpose of updating such description.

All reports and other documents filed by the Registrant with the Commission after the date hereof pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the respective dates of filing of such reports and documents, or the Incorporated Documents.

Any statement contained herein or in any Incorporated Document shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed Incorporated Document modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
Item 4. Description of Securities.
Not applicable.
Item 5. Interests of Named Experts and Counsel.
None.

Item 6. Indemnification of Directors and Officers.
Registrant’s existing certificate of incorporation, as amended to date, or the Amended and Restated Certificate of Incorporation, provides that the Registrant shall indemnify its directors and officers, provided that they have acted in good faith and in a manner which they reasonably believed to be in or not opposed to the best interests of the Registrant and, with respect to any criminal action or proceeding, had no reasonable cause to believe their conduct was unlawful.
This indemnity shall not extend to a suit by or in the right of the Registrant in which any director or officer has been adjudged to be liable to the Registrant, unless and to the extent that the court making such adjudication determines that the director or officer in question is fairly and reasonably entitled to indemnity for expenses that the court deems proper.
The Registrant shall not indemnify any director or officer in respect of a proceeding initiated by such director or officer unless such proceeding was authorized by the Registrant’s board of directors.
Any indemnification of its directors or officers by the Registrant is conditioned on the director or officer in question notifying the Registrant in writing as soon as possible of any proceeding for which indemnity will or could be sought, unless the Registrant has confirmed to the director or officer that it is aware of such proceeding. The



Registrant may elect to participate in or assume the defense of any such proceeding at its own expense. The Registrant shall not be required to indemnify for any amounts paid in settlement without its written consent, which consent will not be unreasonably withheld.
Any indemnified director or officer will have the right to advancement of expenses upon the Registrant’s receipt of written notice therefor and an undertaking by or on behalf of any such director or officer to repay all amounts advanced if it shall ultimately be judicially determined that such person is not entitled to be indemnified.
The Registrant shall not indemnify any director or officer to the extent such director or officer is reimbursed from the proceeds of insurance. In the event the Registrant makes any indemnification payments and the director or officer in question is subsequently reimbursed from the proceeds of insurance, such director or officer shall promptly refund the Registrant to the extent of such insurance reimbursement.
Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended (the “Securities Act”), may be permitted to our directors, officers and controlling persons pursuant to the foregoing, or otherwise, we have been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by us of expenses incurred or paid by a director, officer or controlling person of ours in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

Item 7. Exemption from Registration Claimed.
Not applicable.
Item 8. Exhibits.
The following exhibits are filed as a part of or incorporated by reference into this Registration Statement:
Exhibit
Number
Exhibit DescriptionFiled HerewithIncorporated by Reference herein from Form or ScheduleFiling DateSEC File/ Reg. Number
4.110-Q11/10/2020001-38118
4.210-K3/11/2020001-38118
5.1X
23.1X
23.2X
24.1X
99.1X
107X



Item 9. Undertakings.

(a)    The undersigned Registrant hereby undertakes:
(1)    To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
(i)    To include any prospectus required by Section 10(a)(3) of the Securities Act;
(ii)    To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represents a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement.
(iii)    To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the Registration Statement is on Form S-8 and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.
(2)    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(3)    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
(b)    The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(c)    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.





SIGNATURES
The Registrant. Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in San Diego, California on September 16, 2022.
DERMTECH, INC.
By: /s/ Kevin Sun    
    Name: Kevin Sun
    Title: Chief Financial Officer
Each person whose signature appears below constitutes and appoints John Dobak, M.D. and Kevin Sun, and each of them singly, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them singly, for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of DermTech, Inc., and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in or about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitute may lawfully do or cause to be done by virtue hereof.



Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

SignatureTitleDate
/s/ John Dobak
John Dobak, M.D.
Chief Executive Officer and Director
(Principal Executive Officer)
September 16, 2022
/s/ Kevin Sun
Chief Financial Officer and Treasurer
(Principal Financial and Accounting Officer)
September 16, 2022
Kevin Sun
/s/ Cynthia Collins
Cynthia CollinsDirectorSeptember 16, 2022
Monica TelladoDirectorSeptember 16, 2022
Nathalie Gerschtein KeraudyDirectorSeptember 16, 2022
/s/ Matthew Posard
DirectorSeptember 16, 2022
Herm RosenmanDirectorSeptember 16, 2022
DirectorSeptember 16, 2022
Kirk MalloyDirectorSeptember 16, 2022



Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘S-8’ Filing    Date    Other Filings
Filed on / Effective on:9/16/22
9/1/22
6/30/2210-Q
3/31/2210-Q
3/10/2210-K
12/31/2110-K,  NT 10-K
3/5/2110-K
12/31/2010-K
 List all Filings 


2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/02/23  DermTech, Inc.                    10-K       12/31/22   66:9.9M
11/03/22  DermTech, Inc.                    10-Q        9/30/22   52:7M


11 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/08/22  DermTech, Inc.                    10-Q        6/30/22   56:9.3M
 8/08/22  DermTech, Inc.                    8-K:2,9     8/08/22   11:285K
 7/18/22  DermTech, Inc.                    8-K:5,8,9   7/18/22   11:206K
 5/31/22  DermTech, Inc.                    8-K:5       5/26/22   10:182K                                   ActiveDisclosure/FA
 5/03/22  DermTech, Inc.                    10-Q        3/31/22   57:8.9M                                   ActiveDisclosure/FA
 5/03/22  DermTech, Inc.                    8-K:2,9     5/03/22   11:443K                                   ActiveDisclosure/FA
 4/28/22  DermTech, Inc.                    8-K:1,2     4/22/22   10:172K                                   ActiveDisclosure/FA
 3/10/22  DermTech, Inc.                    10-K       12/31/21   69:17M                                    ActiveDisclosure/FA
 3/05/21  DermTech, Inc.                    10-K       12/31/20   64:9.8M                                   ActiveDisclosure/FA
11/10/20  DermTech, Inc.                    10-Q        9/30/20   54:7.9M                                   ActiveDisclosure/FA
 3/11/20  DermTech, Inc.                    10-K       12/31/19   63:8.4M                                   ActiveDisclosure/FA
Top
Filing Submission 0001651944-22-000045   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., Apr. 27, 1:12:13.2am ET